Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25489291 | 0.96 | CHRM5 (0.45) | CHRM5ADRA2CACHEKDM2B | |
| SCHEMBL19807289 | 0.94 | CHRM5 (0.42) | CHRM5ADRA2CACHEKDM2B | |
| SCHEMBL20756942 | 0.87 | ACHE (0.46) | CHRM5ADRA2CACHESIGMAR1GBA1 | |
| SCHEMBL24491906 | 0.84 | CHRM5 (0.46) | CHRM5ADRA2CACHESIGMAR1GBA1 | |
| SCHEMBL20756456 | 0.82 | ACHE (0.39) | CHRM5ADRA2CACHESIGMAR1KDM2B | |
| SCHEMBL15222417 | 0.82 | CHRM5 (0.50) | CHRM5ADRA2CACHESIGMAR1GBA1 | |
| SCHEMBL25557379 | 0.81 | PIK3CD (0.42) | CHRM5ADRA2CKDM4ESMN1; SMN2 | |
| SCHEMBL25466838 | 0.81 | KCNH2 (0.38) | CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL25489282 | 0.80 | CHRM5 (0.41) | CHRM5ADRA2CACHESIGMAR1GBA1 | |
| SCHEMBL25951515 | 0.79 | CHRM5 (0.30) | CHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | CHRM5 4386/4885ADRA2C 3950/4885ACHE 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.